Table 3 One-year and 2-year rates and standard errors of progression free survival and overall survival by body mass index WHO categories in patients with relapsed and refractory classical Hodgkin lymphoma treated with nivolumab monotherapy
PSF | OS | |||
|---|---|---|---|---|
1-Year | 2-Year | 1-Year | 2-Year | |
% (± SE) | % (± SE) | % (± SE) | % (± SE) | |
All cases (n = 133) | 63.1 (4.3) | 53.8 (4.8) | 87.6 (2.9) | 81.2 (4.0) |
BMI | ||||
Underweight | 54.5 (15.0) | 54.5 (15.0) | 75.0 (12.45) | 60.0 (16.7) |
Normal weight | 67.1 (5.9) | 53.6 (7.0) | 90.6 (3.7) | 85.3 (5.1) |
Overweight | 67.1 (8.6) | 59.4 (9.2) | 93.4 (4.5) | 83.4 (8.1) |
Obese | 49.0 (10.4) | 49.0 (10.4) | 78.5 (8.5) | 78.5 (8.5) |